Investing in High-Potency Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Investing in High-Potency Manufacturing
Market demand for cytotoxic drugs is leading CMOs to expand their API manufacturing and formulation services.

Pharmaceutical Technology

Gains in secondary manufacturing

CMOs involved in dosage-form manufacturing are also expanding capabilities for highly potent substances. Earlier this year, Almac Sciences (Craivagon, Northern Ireland) formed a pact for fill-and-finish services with the Center for Pharmaceutical Science and Technology (CPST) at the University of Kentucky. In February of 2007, the university spun off the CPST into a private company, Coldstream Laboratories. Coldstream will provide intravenous formulation and sterile fill of cytotoxics and potents for clinical-trial applications. CPST opened a new $17-million sterile manufacturing facility in May 2006. By 2011, the Coldstream facility is projected to have annual revenues of $15 million and employ up to 50 science-based and other professional staff. The collaboration positions Almac Sciences in upstream offerings in cytotoxics. Almac also offers contract manufacturing of high-potency APIs at its facility in Craigavon, Northern Ireland.

Baxter BioPharma Solutions (Round Lake, IL) recently completed the lyophilization capacity expansion at its cytotoxic contract-manufacturing facility in Halle, Germany. The expansion added two large-scale lyophilization units to increase the site's total cytotoxic lyophilization capacity to four dedicated lyophilizers.

Encap Drug Delivery (Livingston, Scotland) is building a 3-million ($6.1-million) pharmaceutical development and manufacturing facility in Livingston, Scotland. The facility will include dedicated, high-containment suites for formulation development and the clinical and commercial manufacture of high-potency and cytotoxic compounds. The facility is scheduled to be operational by June 2008.

NextPharma Technologies (London) is investing EUR 16 million ($23 million) to more than double its sterile cytostatics (oncology) manufacturing capacity at Braine l'Alleud, Belgium. The investment adds a second production line to increase lyophilization capacity for the US, European, and Japanese markets. The investment program will be undertaken in stages between mid-2007 and 2010.

Pharmatek Laboratories (San Diego) is adding cytotoxic and high-potency drug-development capabilities to its pharmaceutical chemistry development services. Services for cytotoxic and high-potency compounds include analyticalmethod development, preformulation testing, formulation development, manufacturing for early-phase clinical trials, release testing, and stability testing and storage.

Pharmatek's cytotoxic and high-potency development services will be carried out in a separate dedicated facility. Its manufacturing capability includes two validated and licensed Class 100,000 high-containment suites designed with barrier technology for the CGMP manufacture of final-form drug products.

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ, 08830, tel. 732.346.3072,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here